title: Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel.
abstract: Nephrectomy, immuno-chemotherapy and resection of residual disease have been the treatment of choice for patients with metastatic renal cell carcinoma during the past decades. The aim of this study was to report the long-term results of this treatment approach. Sixty-two patients with metastatic renal cell carcinoma participated in a Phase II study. At diagnosis, 32 patients had localized disease, 30 had metastatic disease and 53 underwent nephrectomy. Metastatic sites were lungs, lymph nodes, bones and liver. Immuno-chemotherapy consisted of: interleukin-2, interferon alpha, 5-fluorouracil and vinblastine. All patients were evaluated for toxicity and response to treatment. CR was achieved in 4 patients and PR in 14. Seven patients, with maximum response to immuno-chemotherapy underwent resection of residual tumor and reached CR. Therefore, CR was achieved in 11 patients (18%) with a median survival of +67 months. Flu-like symptoms were the common side effects. Performance status and histology type significantly affected survival. Nephrectomy, immuno-chemotherapy and resection of residual disease are recommended for patients with metastatic renal cell carcinoma.
authors.affiliation: Department of Oncology, Rambam Medical Center, Haifa, Israel. e_gez@rambam.health.gov.il
authors.forename: E
authors.initials: E
authors.lastname: Gez
authors.forename: R
authors.initials: R
authors.lastname: Rubinov
authors.forename: D
authors.initials: D
authors.lastname: Gaitini
authors.forename: S
authors.initials: S
authors.lastname: Meretyk
authors.forename: L-A
authors.initials: LA
authors.lastname: Best
authors.forename: T
authors.initials: T
authors.lastname: Mashiach
authors.forename: O
authors.initials: O
authors.lastname: Native
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: A
authors.initials: A
authors.lastname: Kuten
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007375:Interleukin-1 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D016898:Interferon-alpha; D007375:Interleukin-1; D014747:Vinblastine; D005472:Fluorouracil